BR112022013270A2 - Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de células - Google Patents
Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de célulasInfo
- Publication number
- BR112022013270A2 BR112022013270A2 BR112022013270A BR112022013270A BR112022013270A2 BR 112022013270 A2 BR112022013270 A2 BR 112022013270A2 BR 112022013270 A BR112022013270 A BR 112022013270A BR 112022013270 A BR112022013270 A BR 112022013270A BR 112022013270 A2 BR112022013270 A2 BR 112022013270A2
- Authority
- BR
- Brazil
- Prior art keywords
- injection
- particles
- chitosan
- aqueous solution
- cells
- Prior art date
Links
- 238000002347 injection Methods 0.000 title abstract 6
- 239000007924 injection Substances 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001661 Chitosan Polymers 0.000 abstract 5
- 239000002245 particle Substances 0.000 abstract 5
- 239000007864 aqueous solution Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000005252 bulbus oculi Anatomy 0.000 abstract 1
- 210000005228 liver tissue Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 210000004923 pancreatic tissue Anatomy 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SISTEMAS E COMPOSIÇÕES FARMACÊUTICAS PARA TRATAMENTO POR INJEÇÃO POR INJEÇÃO DIRETA DE UMA POPULAÇÃO ALVO DE CÉLULAS. A presente invenção refere-se a sistemas e métodos, que são fornecidos para liberar um tratamento terapêutico a uma população alvo de células de um indivíduo. O sistema inclui uma solução aquosa injetável em um frasco fechado com um septo, a solução aquosa injetável formulada para injeção em uma população alvo de células. A solução inclui partículas contendo um agente terapêutico e possuindo um revestimento em torno do agente terapêutico, o revestimento incluindo quitosana de modo a fornecer liberação controlada do agente das partículas. A solução inclui ainda polímero de quitosana na forma de uma matriz de gel de polímero, proporcionando ainda liberação controlada das partículas do ambiente de gel aquoso. Também são fornecidos métodos de fabricação de um pó liofilizado disposto dentro de um frasco contendo polímero de quitosana e partículas revestidas de quitosana, o pó formando a solução aquosa injetável de partículas acima descrita e gel de quitosana após mistura com água. Além disso, são fornecidos métodos de injeção da solução aquosa injetável descrita acima em populações de células direcionadas, incluindo, mas não se limitando a, tumores, globos oculares, tecido pancreático, tecido hepático e tecido pulmonar, a fim de fornecer liberação localizada de agente terapêutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062956795P | 2020-01-03 | 2020-01-03 | |
PCT/US2021/012015 WO2021138646A1 (en) | 2020-01-03 | 2021-01-03 | Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022013270A2 true BR112022013270A2 (pt) | 2022-09-06 |
Family
ID=76687575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022013270A BR112022013270A2 (pt) | 2020-01-03 | 2021-01-03 | Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de células |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230103552A1 (pt) |
EP (1) | EP4084828A4 (pt) |
JP (1) | JP2023509463A (pt) |
KR (1) | KR20220125798A (pt) |
CN (1) | CN115243722A (pt) |
AU (1) | AU2021204918A1 (pt) |
BR (1) | BR112022013270A2 (pt) |
CA (1) | CA3166633A1 (pt) |
WO (1) | WO2021138646A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3015172A1 (en) | 2016-02-18 | 2017-08-24 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
WO2018151849A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
JP2008520547A (ja) * | 2004-10-04 | 2008-06-19 | キューエルティー ユーエスエー,インコーポレイテッド. | 眼部送達のためのポリマー送達処方 |
US7867984B1 (en) * | 2005-01-04 | 2011-01-11 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
ES2562878T3 (es) * | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
WO2009158145A2 (en) * | 2008-05-30 | 2009-12-30 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
US9216152B2 (en) * | 2008-06-27 | 2015-12-22 | Tepha, Inc. | Injectable delivery of microparticles and compositions therefore |
CA3015172A1 (en) * | 2016-02-18 | 2017-08-24 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
-
2021
- 2021-01-03 BR BR112022013270A patent/BR112022013270A2/pt unknown
- 2021-01-03 KR KR1020227026296A patent/KR20220125798A/ko unknown
- 2021-01-03 AU AU2021204918A patent/AU2021204918A1/en active Pending
- 2021-01-03 WO PCT/US2021/012015 patent/WO2021138646A1/en unknown
- 2021-01-03 CN CN202180018850.2A patent/CN115243722A/zh active Pending
- 2021-01-03 JP JP2022541285A patent/JP2023509463A/ja active Pending
- 2021-01-03 CA CA3166633A patent/CA3166633A1/en active Pending
- 2021-01-03 EP EP21736181.5A patent/EP4084828A4/en active Pending
- 2021-01-03 US US17/758,205 patent/US20230103552A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021204918A1 (en) | 2022-07-21 |
WO2021138646A1 (en) | 2021-07-08 |
CN115243722A (zh) | 2022-10-25 |
CA3166633A1 (en) | 2021-07-08 |
EP4084828A1 (en) | 2022-11-09 |
JP2023509463A (ja) | 2023-03-08 |
US20230103552A1 (en) | 2023-04-06 |
KR20220125798A (ko) | 2022-09-14 |
EP4084828A4 (en) | 2024-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022013270A2 (pt) | Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de células | |
Sun et al. | Combating biofilm associated infection in vivo: integration of quorum sensing inhibition and photodynamic treatment based on multidrug delivered hollow carbon nitride sphere | |
US20190142971A1 (en) | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | |
Li et al. | Chitosan-based self-healing hydrogel for bioapplications | |
Laurén et al. | Technetium-99m-labeled nanofibrillar cellulose hydrogel for in vivo drug release | |
ES2333498B1 (es) | Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto. | |
BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
BR112018073699A2 (pt) | amino lipídios de sulfonamida catiônica e amino lipídios zwiteriônico anfifílicos | |
BR112014008932A2 (pt) | bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados | |
BR112016029581B1 (pt) | Propionibacterium acnes geneticamente modificada, composição e seus usos | |
AU2015210769A1 (en) | Methods and products for nucleic acid production and delivery | |
AU2016218977A1 (en) | Nucleic acid products and methods of administration thereof | |
BR112015022432A2 (pt) | microestrutura de matriz para a entrega de agentes ativos | |
CN104114572A (zh) | 经修饰的核苷、核苷酸和核酸组合物 | |
Wang et al. | On-demand drug delivery of triptolide and celastrol by poly (lactic-co-glycolic acid) nanoparticle/triglycerol monostearate-18 hydrogel composite for rheumatoid arthritis treatment | |
BR112018008344A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição | |
Melo et al. | Chitosan-based injectable in situ forming hydrogels containing dopamine-reduced graphene oxide and resveratrol for breast cancer chemo-photothermal therapy | |
BR112022025658A2 (pt) | Método para controlar uma taxa de liberação de um agente terapêutico, dispositivo implantável para liberação de um agente terapêutico, e, formulação de um agente terapêutico | |
Qing et al. | Chemotactic ion-releasing hydrogel for synergistic antibacterial and bone regeneration | |
JP2017502959A5 (pt) | ||
Djoudi et al. | Hyaluronic acid scaffolds for loco-regional therapy in nervous system related disorders | |
WO2022262012A1 (zh) | 一种化学交联透明质酸水凝胶及其制备方法与应用 | |
Chang et al. | Glucosamine-loaded injectable hydrogel promotes autophagy and inhibits apoptosis after cartilage injury | |
BRPI0620268B8 (pt) | composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo | |
Kavanagh et al. | Human CAR-T Cells engineered using the Solupore Ex Vivo Cell Engineering Platform are highly cytotoxic and specific against CD19+ cells in vitro |